Targeted adaptive sampling enables clinical pharmacogenomics testing and genome-wide genotyping
Over 90% of people carry variants that could impact drug efficacy or safety. Here, Peng and Lin et al. validated Oxford Nanopore sequencing for accurate, haplotype-resolved testing of 35 pharmacogenomic targets, achieving high accuracy and enabling genome-wide genotyping — a scalable, cost-effective step towards truly personalised medicine.
Watch Pamela Gan’s talk at London Calling 2025
Sample type: cell lines, human blood